SG11201407619SA - Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof - Google Patents
Schmallenberg virus (sbv) vaccine, methods of production, and uses thereofInfo
- Publication number
- SG11201407619SA SG11201407619SA SG11201407619SA SG11201407619SA SG11201407619SA SG 11201407619S A SG11201407619S A SG 11201407619SA SG 11201407619S A SG11201407619S A SG 11201407619SA SG 11201407619S A SG11201407619S A SG 11201407619SA SG 11201407619S A SG11201407619S A SG 11201407619SA
- Authority
- SG
- Singapore
- Prior art keywords
- ingelheim
- international
- boehringer
- rhein
- gmbh
- Prior art date
Links
- 241000660220 Schmallenberg virus Species 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 3
- 241000282849 Ruminantia Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000283707 Capra Species 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 206010058874 Viraemia Diseases 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000003405 preventing effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12061—Methods of inactivation or attenuation
- C12N2760/12063—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170631 | 2012-06-01 | ||
| EP13157875 | 2013-03-05 | ||
| PCT/US2013/043146 WO2013181270A1 (en) | 2012-06-01 | 2013-05-29 | Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407619SA true SG11201407619SA (en) | 2014-12-30 |
Family
ID=48607368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407619SA SG11201407619SA (en) | 2012-06-01 | 2013-05-29 | Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9370562B2 (enExample) |
| EP (1) | EP2855513B1 (enExample) |
| JP (1) | JP6250649B2 (enExample) |
| CN (1) | CN104350066B (enExample) |
| AR (1) | AR091240A1 (enExample) |
| AU (1) | AU2013267453C1 (enExample) |
| BR (1) | BR112014029515A2 (enExample) |
| CA (1) | CA2872961A1 (enExample) |
| DK (1) | DK2855513T3 (enExample) |
| EA (1) | EA034543B1 (enExample) |
| ES (1) | ES2617351T3 (enExample) |
| IN (1) | IN2014DN08927A (enExample) |
| MX (1) | MX363044B (enExample) |
| PL (1) | PL2855513T3 (enExample) |
| SG (1) | SG11201407619SA (enExample) |
| UY (1) | UY34840A (enExample) |
| WO (1) | WO2013181270A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6250649B2 (ja) | 2012-06-01 | 2017-12-20 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用 |
| EP2855512B1 (en) | 2012-06-01 | 2018-02-28 | Boehringer Ingelheim Vetmedica GmbH | Genomic sequences of schmallenberg virus and uses thereof |
| HK1216006A1 (zh) * | 2013-03-12 | 2016-10-07 | Boehringer Ingelheim Animal Health USA Inc. | 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法 |
| CN104232587B (zh) * | 2014-09-02 | 2016-08-17 | 中国检验检疫科学研究院 | 稳定表达施马伦贝格病毒核衣壳蛋白的细胞系及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0811736B2 (ja) * | 1986-08-07 | 1996-02-07 | 財団法人化学及血清療法研究所 | 牛流行熱・イバラキ病・アカバネ病３種混合不活化ワクチン |
| GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
| US6114108A (en) | 1995-08-29 | 2000-09-05 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of viral nucleic acids |
| US20080226682A1 (en) * | 2007-03-13 | 2008-09-18 | Peros Systems Technologies, Inc. | Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents |
| EP2062594A1 (en) | 2007-11-21 | 2009-05-27 | Wyeth Farma, S.A. | Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
| JP6250649B2 (ja) | 2012-06-01 | 2017-12-20 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用 |
| EP2855512B1 (en) | 2012-06-01 | 2018-02-28 | Boehringer Ingelheim Vetmedica GmbH | Genomic sequences of schmallenberg virus and uses thereof |
-
2013
- 2013-05-29 JP JP2015515159A patent/JP6250649B2/ja not_active Expired - Fee Related
- 2013-05-29 AU AU2013267453A patent/AU2013267453C1/en not_active Ceased
- 2013-05-29 SG SG11201407619SA patent/SG11201407619SA/en unknown
- 2013-05-29 IN IN8927DEN2014 patent/IN2014DN08927A/en unknown
- 2013-05-29 CA CA2872961A patent/CA2872961A1/en active Pending
- 2013-05-29 EA EA201401352A patent/EA034543B1/ru not_active IP Right Cessation
- 2013-05-29 ES ES13728288.5T patent/ES2617351T3/es active Active
- 2013-05-29 MX MX2014014521A patent/MX363044B/es unknown
- 2013-05-29 EP EP13728288.5A patent/EP2855513B1/en active Active
- 2013-05-29 CN CN201380028863.3A patent/CN104350066B/zh active Active
- 2013-05-29 WO PCT/US2013/043146 patent/WO2013181270A1/en not_active Ceased
- 2013-05-29 DK DK13728288.5T patent/DK2855513T3/en active
- 2013-05-29 US US13/904,752 patent/US9370562B2/en active Active
- 2013-05-29 PL PL13728288T patent/PL2855513T3/pl unknown
- 2013-05-29 BR BR112014029515A patent/BR112014029515A2/pt not_active IP Right Cessation
- 2013-05-31 AR ARP130101936 patent/AR091240A1/es not_active Application Discontinuation
- 2013-05-31 UY UY0001034840A patent/UY34840A/es unknown
-
2016
- 2016-05-19 US US15/158,790 patent/US9872897B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9872897B2 (en) | 2018-01-23 |
| AU2013267453A1 (en) | 2014-11-13 |
| EP2855513A1 (en) | 2015-04-08 |
| ES2617351T3 (es) | 2017-06-16 |
| JP2015519367A (ja) | 2015-07-09 |
| JP6250649B2 (ja) | 2017-12-20 |
| EA201401352A1 (ru) | 2015-05-29 |
| CN104350066A (zh) | 2015-02-11 |
| AU2013267453B2 (en) | 2017-04-06 |
| US9370562B2 (en) | 2016-06-21 |
| UY34840A (es) | 2013-12-31 |
| EP2855513B1 (en) | 2016-12-07 |
| PL2855513T3 (pl) | 2017-05-31 |
| WO2013181270A1 (en) | 2013-12-05 |
| EA034543B1 (ru) | 2020-02-19 |
| DK2855513T3 (en) | 2017-03-13 |
| US20160250317A1 (en) | 2016-09-01 |
| AR091240A1 (es) | 2015-01-21 |
| BR112014029515A2 (pt) | 2017-07-25 |
| US20130323277A1 (en) | 2013-12-05 |
| IN2014DN08927A (enExample) | 2015-05-22 |
| CN104350066B (zh) | 2018-06-19 |
| AU2013267453C1 (en) | 2017-08-10 |
| MX363044B (es) | 2019-03-06 |
| CA2872961A1 (en) | 2013-12-05 |
| MX2014014521A (es) | 2015-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408307VA (en) | Needle guard | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201805120YA (en) | Zika virus vaccine | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201407873RA (en) | Endoscopic sympathectomy systems and methods | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201408459VA (en) | Purification of virus like particles | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408292YA (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201907207UA (en) | Pharmaceutical combinations comprising an anti-ly75 antibody | |
| SG11201407597XA (en) | Nucleophilic catalysts for oxime linkage | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201810974QA (en) | Methods and compositions for prostate cancer diagnosis and treatment | |
| SG11201407619SA (en) | Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof |